PASC Post Acute Sequelae of COVID 19QG-PASCNCT06879925
Physiological and QoL Benefits of Qi-Gong in Post-acute Sequelae of Covid-19
A study of PASC Post Acute Sequelae of COVID 19, run by POCHIWU at 2 sites in Taiwan.
Trial summary
The goal of this clinical trial is to determine whether Qi-Gong can improve physiological function and quality of life (QoL) in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC). Study Objectives: To assess whether Qi-Gong improves physiological function in individuals with PASC. Read more about this study
- Who is it for?
- Ages 20 to 100 years
- Conditions the study is for
- PASC Post Acute Sequelae of COVID 19
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 2 sitesTaiwan
- Study dates
- 2 Dec 2024to 7 Apr 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- PASC
- above 20 y/o
Who cannot join
- Those who cannot cooperate
- Severe schizophrenia
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan2 sites, 2 recruiting
- Recruiting
Renhe nursing home
New Taipei City
Manager, +886226365111, mei.lin.w27@gmail.com
- Recruiting
Fuxi nursing home
Taipei
Manager, +886225919087, mei.lin.w27@gmail.com
About this study
Official title: The Effects of Qi-gong on Physiology and Quality of Life in Patients with Post-acute Sequelae of Covid-19
The goal of this clinical trial is to determine whether Qi-Gong can improve physiological function and quality of life (QoL) in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC).
Study Objectives:
To assess whether Qi-Gong improves physiological function in individuals with PASC.
To evaluate whether Qi-Gong enhances quality of life in individuals with PASC.
Study Design:
If a comparison group is included, researchers will compare Qi-Gong with standard care to assess its effectiveness.
Participant Involvement:
Practice Qi-Gong three times per week for three months. Record physiological data monthly.
- Conditions
- PASC Post Acute Sequelae of COVID 19
- Being tested
- QI-GONG and control
- Medical subject headings
- Post-Acute COVID-19 Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QI-GONG and controlBehavioural
QIGONG
| Study group | Role | What they receive |
|---|---|---|
| Qi-Gong Group | Experimental | Experimental Group :Qi-Gong(yijinjing) Receives: Behavioral: QI-GONG and control |
| routine care Group | No intervention | Control Group:routine care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pulmonary Function Test (Forced vital capacity)
FVC，over 80% is better
Measured: From enrollment to the end of treatment at 12 weeks
Pulmonary Function Test (FEV1)
FEV1，over 80% is better
Measured: From enrollment to the end of treatment at 12 weeks
Pulmonary Function Test (FVCFEV1)
FVCFEV1，over 80% is better
Measured: From enrollment to the end of treatment at 12 weeks
Heart rate variability
Low Frequency,40%-60%
Measured: From enrollment to the end of treatment at 12 weeks
Heart rate variability
High Frequency,40%-60%
Measured: From enrollment to the end of treatment at 12 weeks
Heart rate variability
LF/HF,0.6-2.5
Measured: From enrollment to the end of treatment at 12 weeks
Heart rate variability
Heart rate variability ,25ms-70ms
Measured: From enrollment to the end of treatment at 12 weeks
Quality of Life(The short version of the World Health Organization Quality of Life ，WHOQOL-BREF)
WHOQOL-BREF 4 domains,and each one score is 4 - 20. more score more better
Measured: From enrollment to the end of treatment at 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2025
- Study start2 Dec 2024
- Primary completion7 Apr 2025 (estimated)
- Study completion7 Apr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PASC Post Acute Sequelae of COVID 19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Experimental Group:QIGONG Control Group
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- POCHIWU
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, POCHIWU, National Taipei University of Nursing and Health Sciences
- Investigators
- Mei-Hua Wang, Principal investigator, National Taipei University of Nursing and Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06879925
- Sponsor's protocol ID
- CTH-113-3-5-030
- Other IDs
- NTUNHS
- Acronym
- QG-PASC
- Status last verified
- Mar 2025
- First submitted
- 15 Feb 2025
- Last updated
- 17 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Qi-gong on Physiology and Quality of Life in Patients with Post-acute Sequelae of Covid-19
- ClinicalTrials.gov ID
- NCT06879925
- Acronym / sponsor ID
- QG-PASC / CTH-113-3-5-030
- Conditions
- PASC Post Acute Sequelae of COVID 19
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- POCHIWUUniversity, hospital or other
- Study start
- 2 Dec 2024 (actual)
- Primary completion
- 7 Apr 2025 (estimated)
- Study completion
- 7 Apr 2025 (estimated)
- First posted
- 17 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to determine whether Qi-Gong can improve physiological function and quality of life (QoL) in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC).
Study Objectives:
To assess whether Qi-Gong improves physiological function in individuals with PASC.
To evaluate whether Qi-Gong enhances quality of life in individuals with PASC.
Study Design:
If a comparison group is included, researchers will compare Qi-Gong with standard care to assess its effectiveness.
Participant Involvement:
Practice Qi-Gong three times per week for three months. Record physiological data monthly.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Experimental Group:QIGONG Control Group
| Arm | Type | Receives |
|---|---|---|
| Qi-Gong Group | Experimental | Behavioral: QI-GONG and controlExperimental Group :Qi-Gong(yijinjing) |
| routine care Group | No intervention | –Control Group:routine care |
Who may qualify
- Ages
- 20 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- PASC
- above 20 y/o
Key exclusion criteria (2 listed)
- Those who cannot cooperate
- Severe schizophrenia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QI-GONG and controlQIGONG | Behavioural | Qi-Gong Group |
Primary outcome
Pulmonary Function Test (Forced vital capacity)
Time frame: From enrollment to the end of treatment at 12 weeks
FVC，over 80% is better
Pulmonary Function Test (FEV1)
Time frame: From enrollment to the end of treatment at 12 weeks
FEV1，over 80% is better
Pulmonary Function Test (FVCFEV1)
Time frame: From enrollment to the end of treatment at 12 weeks
FVCFEV1，over 80% is better
Heart rate variability
Time frame: From enrollment to the end of treatment at 12 weeks
Low Frequency,40%-60%
Heart rate variability
Time frame: From enrollment to the end of treatment at 12 weeks
High Frequency,40%-60%
Heart rate variability
Time frame: From enrollment to the end of treatment at 12 weeks
LF/HF,0.6-2.5
Heart rate variability
Time frame: From enrollment to the end of treatment at 12 weeks
Heart rate variability ,25ms-70ms
Quality of Life(The short version of the World Health Organization Quality of Life ，WHOQOL-BREF)
Time frame: From enrollment to the end of treatment at 12 weeks
WHOQOL-BREF 4 domains,and each one score is 4 - 20. more score more better
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2025.
- Individual participant dataSharing planned: No
Related trials for PASC Post Acute Sequelae of COVID 19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Active, not recruiting
Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)
Dysexecutive Syndrome, Post-Acute Sequelae of COVID-19
Not yet recruitingPhase 1/2
Taurine Supplementation in Adolescents With Post-COVID Condition
Long COVID, Post COVID-19 Condition
Active, not recruitingObservational study
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mei-Hua Wang principal investigator
National Taipei University of Nursing and Health Sciences
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of PASC Post Acute Sequelae of COVID 19, run by POCHIWU at 2 sites in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Po-Chi Wu (+886900622739, mei.lin.w27@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pulmonary Function Test (Forced vital capacity) (time frame: From enrollment to the end of treatment at 12 weeks). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2025.